NCT01248793View on ClinicalTrials.gov

Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

March 31, 2012

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Placebo

Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20

DRUG

Golimumab

Golimumab 50 mg SC injection every 4 weeks for 48 weeks

DRUG

Golimumab (placebo group)

Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48

Trial Locations (7)

Unknown

Beijing

Chengdu

Guangzhou

Hefei

Jinan

Shanghai

Xi'an

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY